Taylor Hoffman Wealth Management boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 50.1% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 686 shares of the life sciences company’s stock after buying an additional 229 shares during the quarter. Taylor Hoffman Wealth Management’s holdings in Illumina were worth $213,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently modified their holdings of ILMN. Vanguard Group Inc lifted its stake in Illumina by 1.8% during the 3rd quarter. Vanguard Group Inc now owns 10,833,784 shares of the life sciences company’s stock worth $3,976,649,000 after acquiring an additional 188,516 shares in the last quarter. BB&T Corp raised its holdings in Illumina by 30.3% during the fourth quarter. BB&T Corp now owns 3,145 shares of the life sciences company’s stock worth $943,000 after purchasing an additional 731 shares during the last quarter. First Quadrant L P CA grew its position in shares of Illumina by 10.2% in the fourth quarter. First Quadrant L P CA now owns 701 shares of the life sciences company’s stock valued at $210,000 after purchasing an additional 65 shares during the period. We Are One Seven LLC purchased a new stake in Illumina during the fourth quarter valued at about $196,000. Finally, Ingalls & Snyder LLC grew its position in Illumina by 10.5% during the fourth quarter. Ingalls & Snyder LLC now owns 718 shares of the life sciences company’s stock valued at $215,000 after acquiring an additional 68 shares during the period. 90.41% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts have issued reports on the company. BidaskClub raised Illumina from a “hold” rating to a “buy” rating in a research report on Tuesday, April 16th. Canaccord Genuity reissued a “buy” rating and set a $350.00 price target (down previously from $360.00) on shares of Illumina in a research report on Friday, April 26th. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $355.00 price target for the company in a research report on Tuesday, April 2nd. OTR Global downgraded Illumina to a “positive” rating in a research report on Tuesday, April 2nd. Finally, Deutsche Bank downgraded Illumina from a “buy” rating to a “hold” rating and set a $296.53 price target for the company. in a research report on Friday, January 25th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Illumina currently has an average rating of “Buy” and an average price target of $353.58.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, April 25th. The life sciences company reported $1.60 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.34 by $0.26. Illumina had a return on equity of 23.49% and a net margin of 25.06%. The business had revenue of $846.00 million for the quarter, compared to analysts’ expectations of $838.70 million. During the same quarter in the previous year, the firm posted $1.45 earnings per share. The company’s revenue was up 8.2% compared to the same quarter last year. On average, research analysts anticipate that Illumina, Inc. will post 6.68 earnings per share for the current year.
In other news, SVP Aimee L. Hoyt sold 298 shares of the firm’s stock in a transaction that occurred on Tuesday, February 26th. The shares were sold at an average price of $304.63, for a total transaction of $90,779.74. Following the completion of the sale, the senior vice president now owns 2,297 shares of the company’s stock, valued at $699,735.11. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $304.44, for a total transaction of $1,004,652.00. Following the sale, the director now directly owns 282,516 shares of the company’s stock, valued at approximately $86,009,171.04. The disclosure for this sale can be found here. In the last quarter, insiders sold 53,629 shares of company stock worth $16,653,327. Insiders own 0.38% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://baseballnewssource.com/2019/05/25/illumina-inc-ilmn-position-raised-by-taylor-hoffman-wealth-management/3413037.html.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Story: Return on Equity (ROE)
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.